Evidence map›Paper›PMID 40455734›Full record

ArticlePloS one2025

Molecular insights into the role of Estrogen Receptor Beta in Ecdysterone Mediated Anabolic Activity.

Syeda Sumayya Tariq, Madiha Sardar, Muhammad Shafiq, Hendrick Heinz, Mohammad Nur-E-Alam, Aftab Ahmed, Zaheer Ul-Haq

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Syeda Sumayya TariqDr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
Madiha SardarH.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
Muhammad ShafiqH.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
Hendrick HeinzDepartment of Chemical and Biological Engineering, University of Colorado at Boulder, Boulder, Colorado, United States of America.
Mohammad Nur-E-AlamDepartment of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia.
Aftab AhmedDepartment of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, California, United States of America.
Zaheer Ul-HaqDr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.ORCID 0000-0002-8530-8711

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ecdysterone, often dubbed a "natural steroid," has garnered significant attention among athletes for its reputed growth-promoting and anabolic properties. Unlike synthetic anabolic steroids, which are classified as controlled substances, ecdysteroids remain largely unregulated in many countries and are widely marketed as dietary supplements. Notably, ecdysterone has been included in the World Anti-Doping Agency (WADA) monitoring program, highlighting its potential impact on athletic performance and raising questions about its regulation. Emerging evidence indicates that, unlike traditional anabolic steroids that act primarily via the Androgen Receptor (AR), ecdysterone's anabolic effects may be mediated through Estrogen Receptors (ERs), particularly Estrogen Receptor beta (ERβ). Despite these insights, the precise molecular mechanisms underlying ecdysterone's biological activity remain poorly characterized, particularly from an in-silico perspective. This paper aims to address these gaps by exploring ecdysterone's mechanism of action through computational and molecular modeling approaches. This study employs an advanced computational framework to unravel the binding dynamics and interaction mechanisms of ecdysterone with Androgen Receptor (AR), Estrogen Receptor alpha (ERα), and Estrogen Receptor beta (ERβ). Using chemical descriptor analysis, inter-molecular interaction mapping, and all-atom molecular dynamics simulations spanning 250 ns for each system, the study reveals that ecdysterone preferentially binds to ERβ, forming stable and compact complexes characterized by minimal per-residue fluctuations as evident in the average RMSD, RMSF, and Rg values observed for ERβ - Ecdysterone as 1.98 ± 0.31 Å, 1.07 ± 0.52 Å, and 18.44 ± 0.08 Å respectively which are significantly comparable with the ERβ - native complex, while high hydrogen bond occupancy was also observed for ERβ - Ecdysterone complex. Although binding free energy calculations suggest stronger interactions with ERα, the associated high fluctuations diminish its binding efficacy. In contrast, interactions with ERβ remain consistent and robust. Machine learning-based principal component analysis highlights coordinated motion patterns, while free energy profiles demonstrate stable energy basins with minimal variation. These findings underscore the pivotal role of ERβ in mediating ecdysterone's anabolic effects, distinguishing it from traditional androgenic steroids, and provide critical insights into its unique mechanism of action. This work lays the foundation for further exploration of ecdysterone as a potential anabolic agent.

Indexed as

Anabolic AgentsEcdysteroneEstrogen Receptor betaEstrogen Receptor alphaHumansMolecular Docking SimulationMolecular Dynamics SimulationProtein BindingReceptors, AndrogenAnabolic AgentsEcdysteroneEstrogen Receptor alphaEstrogen Receptor betaReceptors, Androgen

Identifiers

PMID40455734
PMCPMC12129227

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.